Albizia schimperiana Oliv. (Leguminosae) is a tree distributed in the highland of Kenya, where it is used as a traditional medicine for the treatment of bacterial and parasitic infections, notably pneumonia and malaria, respectively. Bioassay guided isolation of the CH 2 Cl 2 -MeOH 1:1/ MeOH-H 2 O 9:1 (mixed) extract of A. schimperiana afforded the new bioactive macrocyclic spermine alkaloid, namely 5,14-dimethylbudmunchiamine L1 (1) and three known budmunchiamine analogs 2-4. The structures of the compounds 1-4 were determined by 1D and 2D NMR data, including COSY, HMQC, and HMBC experiments, and ESI-HRMS. Compounds 1 and 3 exhibited significant in vitro antimicrobial activity against a panel of microorganisms, including C. neoformans, methicillin-resistant S. aureus, E. coli, M. intracellulare, and A. fumigatus. In addition, they demonstrated strong in vitro antimalarial activities against chloroquine-susceptible (D6) and -resistant (W2) strains of Plasmodium falciparum with IC 50 s ranging from 120-270 ng/mL. Compounds 1-4 were also evaluated for cytotoxic activity against selected human cancer cell lines and mammalian kidney fibroblasts (VERO cells). It was observed that hydroxyl substitution of the side chain of the budmunchiamines dramatically reduced the cytotoxicity and antimicrobial activity of the alkaloids 2 and 4 without decreasing antimalarial activity.
Albizia schimperiana Oliv. (Leguminosae) is an umbrella-like crown tree 5-30 m high, native to tropical African regions. This tree is more common in drier areas and widely distributed in highland forests in Kenya. The stem bark of A. schimperiana is used indigenously for the treatment of bacterial and parasitic infections, like malaria, pneumonia, and more generally against fever and in pain relief [1] . Earlier investigation of this plant reported the presence of five macrocyclic spermine alkaloids (budmunchiamines) [2] as well as triterpenes [3] . However, a series of unusual macrocyclic spermine alkaloids have also been reported from A. gummifera [4] , A. amara [5, 6] , and A. lebbek [7, 8] .
Interestingly, the MeOH extract of A. gummifera stem bark has been extensively tested and showed antimicrobial [9] , antiparasitic [10, 11] , antitrypanosomal [12] , and mosquito larvicidal [13] activities and it has been shown that only the alkaloidal fraction of the extract retained significant activity [14] . In addition, budmunchiamines isolated from A. gummifera demonstrated in vivo antimalarial activity, suppressing Plasmodium berghei infection in mice after oral administration [14] . In addition, budmunchiamines A-I were investigated for their potential interaction with DNA [5, 6] .
During the course of our drug discovery program at the NCNPR for antiinfective, antiparasitic and anticancer lead candidates from natural sources, an extract of the East African plant A. schimperiana, collected in Kenya, demonstrated potent in vitro activities against Plasmodium falciparum, Cryptococcus neoformans and human cancer cell lines. This led to the bioassay-guided isolation of a 1 (5,14-Dimethylbudmunchiamine L1) R 1 =R 2 =Me, R=H, n=9 2 (6-Hydroxybudmunchiamine K) R 1 =R 2 =Me, R=OH, n=8 3 (5-Normethylbudmunchiamine K) R 1 =H, R 2 =Me, R=H, n=8 4 (6-Hydroxy-5-normethylbudmunchiamine K) R 1 =H, R 2 =Me, R=OH, n=8 5 (budmunchiamine K) R 1 =R 2 =Me, R=H, n=8 new macrocyclic spermine alkaloid, 5,14dimethylbudmunchiamine L1 (1) and three known budmunchiamine analogs 2-4 ( Figure 1 ). In this paper the isolation, spectral features of 1-4, in addition to their antimalarial, antileishmanial, antimicrobial and cytotoxic activities are reported.
Bioassay-guided fractionation of the crude MeOH-H 2 O (9:1) extracts of A. schimperiana resulted in the localization of bioactivities in the CH 2 Cl 2 -MeOH (1:1) soluble fraction. A centrifugal preparative TLC of this fraction using a silica gel disc eluting with 2% Et 2 NH in CHCl 3 yielded compounds 1-4 with yields of 0.003%, 0.0028%, 0.0036% and 0.004%, respectively. The structures of 1-4 were established by 1 H and 13 C NMR data, mainly 2D NMR COSY, HMQC, HMBC and NOESY experiments, and HRMS. Compounds 2-4 were identified as 6-hydroxybudmunchiamine K, 5normethylbudmunchiamine K and 6-hydroxy-5normethylbudmunchiamine K, respectively, by comparison of their NMR and MS data with those reported previously [3, 4] .
Compound 1 was isolated as an amorphous solid and analyzed by positive ion ESIHRMS as C 32 H 67 N 4 O; m/z 523.5341 [M+H] + (calculated for C 32 H 67 N 4 O 523.5315). It was found to be homogenous on silica TLC and reactive with Dragendorff's reagent. Its macrocyclic spermine carbon skeleton with four nitrogen atoms attached to an alkyl side chain was suggested from the 1 H and 13 C NMR [3, 4] .
The spectral data [NMR (Table 1 ) and MS [(M + 522)] of 5,14-dimethylbudmunchiamine L1 (1) were in close agreement with the known spermine alkaloid budmunchiamine K (5) (M + 508) [4] , except for the differences associated with presence of an additional methylene group at the alkylated side chain. Compound 1 showed the presence of an amide carbonyl (δ C-2 172.9), three N-Me groups (δ N-5-Me 35.3, δ N-9-Me 43.4 and δ N-14-Me 42.8) and an NH proton at δ 8.62, which was consistent with those reported for budmunchiamine K (5). Structure 1 was unambiguously established by 2D NMR spectroscopy ( 1 H-1 H COSY, 1 H-13 C HMQC, and 1 H-13 C HMBC) experiments. The HMBC experiment established the assignments of the amide carbonyl group and alkyl side chain at C-2 and C-4, respectively, and the N-Me at N-5 position by long-range correlations between δ H-4 2.80 and δ C-2 172.9, δ C-3 37.2, δ C-2' 27.8, and between δ N-5-Me 35.3 and δ C-4 61.5, δ C-6 52.0. Based on this data, compound 1 was established as 5,14-dimethylbudmunchiamine L1.
Compounds 1-4 exhibited in vitro antimalarial activity against P. falciparum D6 (chloroquinesusceptible) and W2 (chloroquine-resistant) strains with IC 50 values ranging from 120-270 ng/mL ( Table 2 ) and all compounds were found to be almost equally active. Compounds 1-4 also showed strong antileishmanial activity (Table 3) , where 1 and 4 were equipotent with pentamidine, whereas 3 was more potent than pentamidine. The isolated compounds 1 and 3 exhibited significant in vitro antimicrobial activity against a panel of (Tables 4,  5 ). Among the compounds 1-4 tested for cytotoxicity against selected human cancer cell lines and VERO cells, only 1 and 3 with the non-hydroxylated alkyl side chain exhibited moderate toxicities (Table 6 ). By contrast hydroxylated derivatives 2 and 4 showed weak cytotoxicities and antimicrobial activities without decreasing antimalarial and antileishmanial activities. The in vitro antiparasitic activity of the isolated budmunchiamines did not vary significantly with substitution pattern and length of the alkylated side chain, while cytotoxicity diminished upon hydroxylation at C-6´ of the alkyl side chain. This also appears to be the first report of 1 from a natural source. 
Experimental

General Experimental Procedures
6-Hydroxybudmunchiamine K (2)
Amorphous solid.
[α] D 25 : +2.4 (c 0.5, MeOH). The spectral data (IR, 1 H and 13 C NMR) were identical to those reported in the literature [4] . HRESIMS m/z 525.5079 [M+H] + (calcd. for C 31 H 65 N 4 O 2 , 525.5107). The spectral data (IR, 1 H and 13 C NMR) were identical to those reported in the literature [3] .
5-Normethylbudmunchiamine
Antimalarial/ Parasite LDH Assay:
The in vitro antimalarial activity was measured by a colorimetric assay that determines the parasitic lactate dehydrogenase (pLDH) activity [15] [16] [17] . The assay was performed in 96-well microplate and included two P. falciparum strains [Sierra Leone D6 (chloroquine-sensitive) and Indochina W2 (chloroquine-resistant)]. For the assay, a suspension of red blood cells infected with P. falciparum (D6 or W2) strains (200 μL, with 2% parasitemia and 2% hematocrit in RPMI -1640 medium supplemented with 10% human serum and 60 μg/mL amikacin) was added to the wells of a 96-well plate containing 10 μL of test samples at various concentrations. The plate was flushed with a gas mixture of 90% N 2 , 5% O 2 , and 5% CO 2 , in a modular incubation chamber (Billups-Rothenberg, 4464 M) and incubated at 37°C, for 72 h. Plasmodial LDH activity was determined by using Malstat™ reagent (Flow Inc., Portland, OR). The IC 50 values were computed from the dose response curves generated by plotting percent growth against test concentrations. DMSO, artemisinin and chloroquine were included in each assay as vehicle and drug controls, respectively. The selectivity index (SI) of antimalarial activity was determined by measuring the cytotoxicity of samples towards mammalian cells (VERO; monkey kidney fibroblasts).
Antileishmanial Assay: Antileishmanial activity of the compounds was tested in vitro on a culture of Leishmania donovani promastigotes. In a 96 well microplate assay compounds with appropriate dilution were added to the Leishmania promastigotes culture (2x10 6 cells/mL). The plates were incubated at 26°C for 72 hours and growth of Leishmania promastigotes was determined by Alamar blue assay [18] . Pentamidine and amphotericin B were used as standard antileishmanial agents. IC 50 values for each compound were computed from the growth inhibition curve. 
Cytotoxicity Assay:
The in vitro cytotoxic activity was determined against four human cancer cell lines (SK-MEL, KB, BT-549 and SK-OV-3) and monkey kidney fibroblasts (VERO) and pig kidney epithelial cells (LLC-PK 11 ) ( Table 5 ). All cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). The assay was performed in 96-well tissue culture-treated microplates. Cells were seeded at a density of 25000 cells/well and incubated for 24 hours. Samples at different concentrations were added and plates were again incubated for 48 hours. The number of viable cells was determined using Neutral Red according to a modification of the procedure of Borenfreund et al. (1990) [23] . IC 50 values were determined from dose response curves of percent growth inhibition against test concentrations. Doxorubicin was used as a positive control, while DMSO was used as the negative (vehicle) control.
